Timing of hepatitis C treatment initiation and retention in office-based opioid treatment with buprenorphine: a retrospective cohort study
Abstract Background This study examined associations between receipt of hepatitis C (HCV) treatment and retention in office-based opioid treatment (OBOT) care. Methods We conducted a retrospective cohort study of HCV-infected patients who initiated OBOT treatment between December 2015 and March 2021...
Main Authors: | Mary L. Geist, Andrea C. Radick, Judith I. Tsui, Kendra L. Blalock, Addy Adwell, Elsabeth Tamru, Nancy C. Connolly, Jocelyn R. James |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2023-05-01
|
Series: | Addiction Science & Clinical Practice |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13722-023-00389-8 |
Similar Items
-
Comparison of Buprenorphine and Buprenorphine/naloxone in Detoxification of Opioid-dependent Men
by: Hassan Ziaaddini, et al.
Published: (2018-12-01) -
Buprenorphine Induction Using Microdosing for the Management of Opioid Use Disorder in Pregnancy
by: Neil B. Patel, et al.
Published: (2024-01-01) -
Protocol for harmonization of randomized trials testing the addition of behavioral therapy to buprenorphine for opioid use disorder
by: R. Kathryn McHugh, et al.
Published: (2024-06-01) -
Measuring time in buprenorphine treatment stages among people with HIV and opioid use disorder by retention definition and its association with cocaine and hazardous alcohol use
by: Jarratt D. Pytell, et al.
Published: (2023-09-01) -
Factors in rural community buprenorphine dispensing
by: Erin G. Major, et al.
Published: (2023-03-01)